Literature DB >> 8740053

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.

S Schlegel1, R Schlösser, C Hiemke, O Nickel, A Bockisch, K Hahn.   

Abstract

By the application of 123([123I]IBZM), an iodine-labelled dopamine D2-receptor antagonist, brain D2 receptors in humans can be visualized with single photon emission computed tomography (SPECT). The ratio of IBZM binding to striatal regions versus binding to frontal cortex (ST/FC ratio) provided a semiquantitative measurement of D2 receptor binding in the striatum. This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Prolactin levels were positively correlated with D2 receptor occupancy, reflecting at least in part a comparable dopamine receptor antagonism in different dopaminergic pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740053     DOI: 10.1007/bf02246671

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Molecular biology of dopamine receptors.

Authors:  D R Sibley; F J Monsma
Journal:  Trends Pharmacol Sci       Date:  1992-02       Impact factor: 14.819

3.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency.

Authors:  S J Peroutka; S H Synder
Journal:  Am J Psychiatry       Date:  1980-12       Impact factor: 18.112

5.  Blood to brain distribution of neuroleptics.

Authors:  T Sunderland; B M Cohen
Journal:  Psychiatry Res       Date:  1987-04       Impact factor: 3.222

Review 6.  Pharmacology of antidepressants--characteristics of the ideal drug.

Authors:  E Richelson
Journal:  Mayo Clin Proc       Date:  1994-11       Impact factor: 7.616

7.  In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.

Authors:  H F Kung; A Alavi; W Chang; M P Kung; J W Keyes; M G Velchik; J Billings; S Pan; R Noto
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

Review 8.  D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.

Authors:  R Schlösser; S Schlegel
Journal:  J Neural Transm Gen Sect       Date:  1995

9.  D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.

Authors:  J Scherer; K Tatsch; J Schwarz; W H Oertel; M Konjarczyk; M Albus
Journal:  Acta Psychiatr Scand       Date:  1994-10       Impact factor: 6.392

  9 in total
  6 in total

1.  Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model.

Authors:  Maria Letizia Trincavelli; Serena Cuboni; Mario Catena Dell'osso; Roberto Maggio; Karl-Norbert Klotz; Francesca Novi; Anna Panighini; Simona Daniele; Claudia Martini
Journal:  Purinergic Signal       Date:  2010-10-12       Impact factor: 3.765

Review 2.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

3.  Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2 /D3 Receptor Antagonist: Phase I Single- and Multiple-Ascending Dose Studies in Healthy Japanese Participants.

Authors:  Takayoshi Yamaguchi; Kentarou Kudou; Hiroyuki Okamoto; Chunlin Chen; Roger Whiting; Hisakuni Sekino
Journal:  Clin Pharmacol Drug Dev       Date:  2021-12-29

4.  Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.

Authors:  Hong Liu-Seifert; Bruce J Kinon; Christopher J Tennant; Jennifer Sniadecki; Jan Volavka
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

5.  Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.

Authors:  Rogelio Apiquian; Ana Fresán; Camilo de la Fuente-Sandoval; Rosa-Elena Ulloa; Humberto Nicolini
Journal:  BMC Psychiatry       Date:  2004-04-27       Impact factor: 3.630

6.  Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.

Authors:  Roger L Whiting; Borje Darpo; Chunlin Chen; Margaret Fletcher; Dan Combs; Hongqi Xue; Randall R Stoltz
Journal:  Clin Pharmacol Drug Dev       Date:  2021-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.